Momenta Presents Three Glatopa (glatiramer acetate injection) Posters at ECTRIMS 2015 Meeting

CAMBRIDGE, Mass., Oct. 01, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. MNTA, a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of three posters summarizing the key data developed to demonstrate equivalence between Glatopa^TM and daily COPAXONE^® 20 mg (glatiramer acetate injection). The posters will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, and will summarize the overall approach used to evaluate equivalence of the two glatiramer acetate products as well as showcase numerous examples of biological and other key assays.

Poster Presentation Details

Title: "Comparative gene expression profiling between Glatopa™ and Copaxone^® 20 mg"
Poster Number: P641
Session Title: Poster Session I
Session Date: Thursday, 8 October 2015
Presenting Time: 15:45 – 17:00 hr

Title: "Use of multiple, high resolution, orthogonal assays for demonstration of biological and immunological equivalence of Glatopa™ and Copaxone^® 20 mg"
Poster Number: P647
Session Title: Poster Session I
Session Date: Thursday, 8 October 2015
Presenting Time: 15:45 – 17:00 hr

Title: "Demonstration of equivalence between Glatopa™ and Copaxone^® 20 mg"
Poster Number: P1143
Session Title: Poster Session II
Session Date: Friday, 9 October 2015
Presenting Time: 15:30 – 17:00 hr

About Glatopa^TM

Once daily Glatopa (glatiramer acetate injection), developed in collaboration with Sandoz, is the first FDA-approved generic version of daily COPAXONE^® 20 mg for patients with relapsing forms of multiple sclerosis. Produced entirely in the United States, once daily Glatopa has been determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, and is an "AP" rated, fully-substitutable product. As a therapeutically equivalent generic product, once daily Glatopa contains the same active ingredients, route of administration, strength, and dosage form, and can be substituted with the full expectation that Glatopa will produce the same clinical effect and safety profile as daily COPAXONE 20 mg. Daily COPAXONE 20 mg is one of the leading products marketed to treat multiple sclerosis, and is frequently prescribed as a first-line therapy in newly diagnosed patients.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA.  Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

COPAXONE is a registered trademark of Teva Pharmaceuticals. Glatopa is a trademark of Novartis AG.